ArticleCureus2025
Breaking the Seizure Cycle: Surgical Outcomes of Medial Temporal Lobectomy in Drug-Resistant Epilepsy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedial temporal lobe (MTL) lesions are among the most common causes of drug-resistant epilepsy. Surgical management typically involves lesion excision, with or without amygdalohippocampectomy. An alternative approach includes selective hippocampal transection to disrupt the epileptogenic circuit without affecting the memory circuit
methodsThis is a prospective cohort interventional study of consecutive series of patients coming to Al-Azhar University Hospitals at the time between 2022 and 2024 presented with drug-resistant temporal lobe epilepsy (TLE) and treated with excision of the lesions in the MTL with or without amygdalohippocampectomy. Postoperative seizure control was assessed using the Engel classification scale during follow-up and anti-epileptic drug (AED) withdrawal.
resultsThe Engel classification scale was used at follow-up and AED withdrawal to evaluate postoperative seizure control. The results indicated that seizure control improved after medial temporal lobectomy. The final follow-up showed that 15 respondents (75%) reached Engel class I which means they had no seizures and five respondents (25%) had Engel class II, which means they had rare, non-disabling seizures. These results show that medial temporal lobectomy is effective in reducing seizure frequency and improving the quality of life of patients.
conclusionA medial temporal lobectomy, alone or in combination with amygdalohippocampectomy, serves as an effective surgical treatment for drug-resistant TLE. Most patients experience both a reduction in seizure frequency and severity while seizure freedom occurs in the majority after the procedure. These results support surgical management as an essential treatment option for medically refractory epilepsy and highlight the importance of identifying patients for early surgical evaluation. More studies with bigger sample sizes along with extended follow-up periods should be performed to improve patient selection criteria and surgical methods that enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.